Document Detail

C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients.
MedLine Citation:
PMID:  21238518     Owner:  NLM     Status:  MEDLINE    
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) is a major hepatic consequence of obesity. It has been suggested that the high sensitivity C-reactive protein (hs-CRP) is an obesity-independent surrogate marker of severity of NAFLD, especially development of non-alcoholic steato-hepatitis (NASH), but this remains controversial. We aimed to investigate whether associations between various features of NAFLD and hs-CRP are independent of body mass index (BMI) in its broad range among obese patients.
METHODS: A total of 627 obese adults (80% females), representing three cohorts from France and Belgium, had information on liver histology obtained from liver biopsies and measures of hs-CRP and BMI. We investigated whether the different features of NAFLD and BMI were associated with hs-CRP, with and without mutual adjustments using linear regression.
RESULTS: BMI and hs-CRP were strongly associated. Per every 10% increase in BMI the hs-CRP level increased by 19-20% (p<0.001), and adjustment for NAFLD-stage (including no-NAFLD) did not influence the association. We found no BMI-independent association between NASH and hs-CRP. However, a positive association between degree of steatosis and hs-CRP was observed (p<0.05) and this effect remained significant after adjusting for BMI, lobular inflammation, hepatocyte ballooning, and fibrosis. We found no significant associations between the other features of NAFLD and hs-CRP.
CONCLUSIONS: This study indicates that it is the accumulation of fat -both in the adipose tissue and in liver steatosis- that leads to increased hs-CRP levels among obese patients. Thus, hs-CRP may be a marker of steatosis, but not of severity of NAFLD, in obese patients.
Esther Zimmermann; Rodolphe Anty; Joan Tordjman; An Verrijken; Philippe Gual; Albert Tran; Antonio Iannelli; Jean Gugenheim; Pierre Bedossa; Sven Francque; Yannick Le Marchand-Brustel; Karine Clement; Luc Van Gaal; Thorkild I A Sørensen; Tine Jess
Related Documents :
2388668 - Cerebrovascular complications of the use of the "crack" form of alkaloidal cocaine.
18299138 - Predictors of survival and functional outcome in acute stroke patients admitted to the ...
1209788 - Stroke before fifty. experiences from a five-year study.
6736978 - Predicting the outcome of acute stroke: a prognostic score.
17666088 - High risk of pituitary dysfunction due to aneurysmal subarachnoid haemorrhage: a prospe...
25200638 - P-wave duration in lead avr and the risk of atrial fibrillation in hypertension.
Publication Detail:
Type:  Journal Article     Date:  2011-01-14
Journal Detail:
Title:  Journal of hepatology     Volume:  55     ISSN:  1600-0641     ISO Abbreviation:  J. Hepatol.     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-08-19     Completed Date:  2012-01-23     Revised Date:  2012-08-24    
Medline Journal Info:
Nlm Unique ID:  8503886     Medline TA:  J Hepatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  660-5     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Institute of Preventive Medicine, Copenhagen University Hospital, Copenhagen, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / metabolism
Body Mass Index*
C-Reactive Protein / metabolism*
Fatty Liver / complications,  metabolism*,  pathology*
Linear Models
Middle Aged
Obesity / complications,  metabolism*
Severity of Illness Index
Young Adult
Reg. No./Substance:
0/Biological Markers; 9007-41-4/C-Reactive Protein
Comment In:
J Hepatol. 2012 Feb;56(2):507-8; author reply 508-10   [PMID:  21888877 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectiv...
Next Document:  Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and ...